Combined cytotoxic chemotherapy and immunotherapy of cancer: modern times

Monoclonal antibodies targeting programmed cell death 1/programmed cell death ligand 1 (PD-1/PD-L1) immune checkpoints have improved the treatments of cancers. However, not all patients equally benefit from immunotherapy. The use of cytotoxic drugs is practically inevitable to treat advanced cancers...

Descripción completa

Detalles Bibliográficos
Autores principales: Bailly, Christian, Thuru, Xavier, Quesnel, Bruno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Survey and Summary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8209987/
https://www.ncbi.nlm.nih.gov/pubmed/34316682
http://dx.doi.org/10.1093/narcan/zcaa002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8209987/
https://www.ncbi.nlm.nih.gov/pubmed/34316682
http://dx.doi.org/10.1093/narcan/zcaa002

Ejemplares similares